Key Takeaways
- US B2C pivot is working, but the transition is noisy: First-half FY27 US revenue already exceeded all of FY26, yet Q2 US revenue declined sequentially and PBIT margins fell as the company deliberately walks away from B2B deals and milestone revenue.
- Self-imposed slowdown masks underlying momentum: Two older injectable lines are down for upgrades until December, and product launches were rationalized from 14-plus to 10, both conscious choices that suppressed near-term output while the contribution margin actually improved.
- Cash flow dipped on deliberate inventory and receivables build: CFO fell to INR205 crores from INR250 crores last year, driven by a ~INR115 crore inventory increase and ~INR70 crore receivables increase, both expected to normalize by March.
- The 2030 vision is clear, but near-term quantification is thin: Management declined to provide specific return-on-capital figures for Mexico and oncology acquisitions, a 2030 PAT target, or margin drawdown scenarios for FY27–FY28, asking for 2–3 years of patience.
- What to watch next quarter: Whether the upgraded lines restart on schedule in December, whether US revenue regains the Q1 run-rate, and whether the Mexico distribution acquisition closes after the Chairman's January visit.
US Business: The B2C Transition
- Revenue milestone: First-half FY27 US realization of INR103 crores already surpassed full FY26 turnover of INR92 crores, driven equally by US and LATAM markets.
- QoQ decline explained: US business fell sequentially because the company is not pursuing new B2B deals or milestone revenue to a large extent, and some rather large milestone revenue was accrued in Q1 compared to Q2.
- Margin compression is transitional: PBIT margin fell in percentage terms due to the B2B-to-B2C shift, which management described as "choppy waters" in EBITDA and bottom line, while contribution margins remained stable or improved, meaning no price erosion and cost control is intact.
- Line upgrades constrain output: Two older lines (Line 1 and Line 3) are being upgraded with downtime expected until December, a self-imposed drag that will ease in Q4.
- Product rationalization: Planned US new products reduced from 14-plus to 10 because some products that had 2–3 players at the development stage now have 7–8 by launch time, so the company is focusing on product excellence over numbers.
- Volume-based reality: US will continue to be volume-based sales; value-based sales come only from technically superior products or unique business models.
C.C. Paarthipan: "This margins which has come down is the one which makes me to go to the market actually starting from January, because there are some markets you understand you can actually manage. You can also create new versions in our business, but there are some markets which are monopolies and near place where you have to work with the system."
CSU & LATAM: The Direct-to-Last-Mile Bet
- CSU traction accelerating: Daily average sales nearly doubled from $33,000 to $61,000; first-half FY27 sales surpassed full previous year sales; added several direct sales contracts with large and small integrated delivery networks alongside 3 large wholesalers.
- LATAM model shift: In larger geographies (Mexico, Brazil, Chile, Colombia), the strategy is to eliminate intermediaries and go direct from manufacturing to the last mile, selling to small chains, wholesalers, and individual pharmacies.
- Mexico distribution acquisition: Due diligence has started; the Chairman's January visit is expected to complete the acquisition, which will give the company its own distribution infrastructure in the market.
- Mexico manufacturing: Planning to start a facility for liquid orals and IV fluids, with exports to Central American countries in own trucks and storage in own warehouses, expected to increase both top and bottom line for the region.
- China asset-light model, second innings: Plan to import drug substances from China for biosimilar fill-finish in the COL facility, plus large-volume APIs that are cost-competitive; the volume-based purchase introduction in China has created price erosion for local companies, opening a sourcing opportunity.
C.C. Paarthipan: "In a commodity world, there are only 3 ways to win. Be cheaper. Number 2, be faster. And number 3, be different. The first 2, I think they are temporary, and the third is more durable."
Facilities & Capex: Building for 2030
- COL2 timeline slips again: Completion target moved to August 2027 (previously December '26, then March '27, then August '27); 2 out of 6 lines have arrived; all aseptic products will be manufactured through isolator technology per latest FDA and EU Annex 1 guidelines.
- Revenue lag from COL2: 15 to 18 months from facility completion to revenue, due to site transfer, stability runs, filing, and inspection requirements, meaning meaningful revenue is expected FY28–'29 and beyond.
- Oncology injectable facility: Capitalized in April, contributing to the considerable depreciation increase versus last year.
- Oncology API site: Coming up before the end of the next calendar year; first few DMFs expected to be filed within the next year.
- CRO expansion: Expanding from 72 beds to 120 beds by end of FY27, targeting six to eight BE studies per month.
- Capex fully self-funded: All capex (COL2 INR500–600 crores, COL INR100 crores, OSD INR120–150 crores, plus Mexico facility via Caplin Far East Limited) to be funded through own accruals without borrowing.
- Digitization push: LIMS completed in most areas; factory expected to become paperless in 2–3 months with video SOPs, biometrics, CCTV 24/7, quality oversight team, and AI cameras in progress.
C.C. Paarthipan: "We don't try to grow on shaky ground... We always systematize before we scale."
Margins, Costs & Cash Flow
- Gross profit improved ~1.5%: Driven by orders taken on a P&L basis (high-cost, high-price products) and engagement of commission agents to secure those orders.
- Opex variability: Operating expenses slightly up on freight and certain selling expenses linked to the P&L orders; management says this varies quarter to quarter and will get set right by Q4.
- Freight cost headwind: Freight has gone up in the last 3–4 months, with the global situation not conducive for air or sea freight, and August–October typically sees seasonal increases for Christmas and holiday season in the US and Latin America.
- Freight fully recovered in pricing: Most subsidiaries receive goods on a CIF basis; prices have compensated for freight increases; contribution margin went up 1.5% over the previous quarter, more than offsetting the freight increase.
- H1 margin expansion intact: H1-to-H1 EBITDA grew from 29.5% to 34.2%; PBT grew from 19.9% to 23.5%, confirming that Q2 was an "aberration" rather than a trend reversal.
- Cash flow from operations dipped: Declined to INR205 crores from INR250 crores last year due to a conscious decision to increase inventory (~INR115 crores) and receivables (~INR70 crores); inventory expected to normalize by March with a benchmark of 120–150 days; government tender receivables partly expected in Q4.
- No hedging policy: Management does not hedge, citing a past loss and natural hedging via China imports.
Inorganic Opportunities & Capital Allocation
- US oncology asset acquisitions: Evaluating filed and approved oncology products in the US to get a kickstart; due diligence underway.
- Product registration acquisitions: Opportunities to acquire product registrations in LATAM and the US.
- Mexico distribution acquisition: Due diligence started; Chairman's January visit expected to complete it.
- Cash reserves earmarked for M&A: Management prefers to keep liquidity for a potential extraordinary and meaningful acquisition rather than buybacks; an acquisition could happen 6 months from now or after 2 years, and is "not in the company's hands."
- No specifics on returns: Management declined to quantify expected spend or return on capital for the Mexico distribution and oncology ANDA acquisitions, calling it "a little too early to get into those areas right now."
Raw Material & External Risks
- Raw material prices will continue to rise: Management acknowledged that geopolitical risk, wars, and tariff wars will persist and are beyond the company's control, but stated that the company "loves to hit the problems" and does not allow them to affect the business.
- Freight as a pass-through: Because most subsidiaries receive goods on a CIF basis and prices have compensated for freight increases, the contribution margin actually improved, insulating the P&L from the freight spike.
- US FDA inspection at Gummidipoondi: Occurred in August; company responded comprehensively and sent monthly updates; classification pending as of the call; some remediation measures completed, some work in progress.
C.C. Paarthipan: "Having waited with us actually for so long, we're not telling you actually that, you know, we are not in a position to show you the sunshine. We will definitely show you. It's a question of time. That's what I'm telling. That time also is not very far. It's 2-3 years maximum."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US revenue growth | 20% to 25% growth target for FY27 (Caplin Steriles) | FY27 |
| US margin recovery | Q3 and Q4 margins back on rails compared to last year's percentages, if not better (Caplin Steriles) | Q3–Q4 FY27 |
| PAT margin | Well on target to yield 25–26% PAT | FY27 |
| Effective tax rate | Around 20% to 21% | Full year FY27 |
| Inventory normalization | Inventory to come down to normal levels (120–150 days benchmark) | By March |
| CSU revenue and profitability | Double revenue and profitability | FY27 |
| US new product launches | 10 products | Next financial year |
| COL2 facility completion | Completion with 6 injectable lines including ophthalmic and blow-fill seal | August 2027 |
| COL2 first revenue | 15–18 months from completion to revenue (site transfer, stability, filing, inspection) | FY28–'29 and beyond |
| CRO capacity | Expand from 72 to 120 beds; target 6–8 BE studies per month | End of FY27 |
| Oncology API site | Operational | Before end of next calendar year |
| First API DMF filings | First few DMFs from API site | Within next year |
| Paperless factory | Entire digitization, video SOP, paperless factory completed | 3 months |
| Line 1 and Line 3 upgrades | Downtime until December, then production resumes | December |
| Mexico distribution acquisition | Chairman's January visit expected to complete the acquisition | January |
| Best performance | "Sunshine" for shareholders; best performance starting | 2-3 years from now |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Operating revenue | ₹1,240 cr, +18.2% YoY, equally distributed between US and LATAM |
| EBITDA margin | 38.7% |
| PBT margin | 38% |
| PAT margin | 27.2% |
| Effective tax rate | ~15%; full-year target 20–21% |
| Gross profit improvement | +1.5% over previous quarter |
| Cash and cash equivalents | ~₹1,500 cr |
| Net worth | ₹3,963 cr |
| Cash flow from operations | ₹205 cr, vs ₹250 cr last year |
| Inventory increase | ~₹115 cr; 50% to be sold this year, ₹45 cr toward supply tender |
| Receivables increase | ~₹70 cr, from government tenders supplied in last 6 months |
| Capex spent (current year) | >₹130 cr, mostly advance payments for lines |
| COL2 capex planned | ₹500–600 cr over next 12–18 months |
| Caplin One Labs (OSD) capex | ₹120–150 cr over next 12 months |
| CSL revenue contribution | ₹271 cr, +21% over previous year |
| US business H1 FY27 realization | ₹103 cr, exceeding full FY26 turnover of ₹92 cr |
| Caplin Steriles products launched in US | 40 |
| CSU daily average sales | $61,000, nearly doubled from $33,000 last year |
| CSU FY27 expectation | Revenue and profitability to double |
| US new products planned (next financial year) | 10 |
| Pre-filled syringe products | 2 exhibit batches completed, 12 under development |
| APIs scaled up | 5 (4 secondary source, 1 primary source) |
| CRO bed expansion | From 72 to 120 beds by end of FY27; target 6–8 BE studies per month |
| COL2 facility completion | Expected by August '27 |
| Inventory days (benchmark) | 120–150 days |
| US business H1 EBITDA | 34.2%, up from 29.5% H1 last year |
| US business H1 PBT | 23.5%, up from 19.9% H1 last year |
| US business FY27 growth target | 20–25% |
| Exports from China | ~30% of goods |